101P Quality of life (QoL) outcomes in patients (pts) with zanidatamab (zani)-treated HER2-positive (HER2+) biliary tract cancer (BTC) in the phase IIb HERIZON-BTC-01 studyHarpreet Wasan, Shubham Pant, Hongjo Choi et al.|Annals of Oncology|2023Cited by 2
132MO Zanidatamab (ZW25; Zani) in patients (pts) with previously treated advanced human epidermal growth factor receptor 2 (HER2)-amplified biliary tract cancer (BTC): Asia subgroup analysis of the phase IIb HERIZON-BTC-01 studyHsin‐Yun Sun, D-Y. Oh, Jae‐Weon Kim et al.|Annals of Oncology|2023Cited by 0